This article is more than 5 years old. Information may no longer be current.
Study: Systemic cyclosporin A has limited effect in corneal transplants
Click Here to Manage Email Alerts
NAHARIYA, Israel — In repeated corneal transplants, systemic cyclosporin A has a limited beneficial effect in preventing immune graft rejection, according to a study.
Researchers here treated 21 patients with 28 repeated corneal transplants with cyclosporin A for a mean of 12 months and followed them for a mean of 26 months. Twelve regrafts not treated with cyclosporin A served as a control group.
Nine of the 28 regrafts treated with cyclosporin A remained clear. The treated group had a statistically higher graft survival rate than the non-treated group during the first year. Once immune regraft rejection occurred, the regraft failed despite treatment with cyclosporin A and extensive topical and systemic corticosteroids. Nine regrafts had immune graft rejection, and all ultimately failed, compared with five in the untreated regraft group.
The study is published in the September issue of British Journal of Ophthalmology.